This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;301(1):23-24.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New Orleans—Researchers have demonstrated that a new primary prevention strategy may reduce cardiovascular events in certain patients at risk of cardiovascular disease.

At the Scientific Sessions of the American Heart Association (AHA) held here in November, scientists reported that among apparently healthy patients with elevated levels of high-sensitivity C-reactive protein (hsCRP, an inflammatory biomarker) but without elevated low-density lipoprotein cholesterol (LDL-C) levels (< 130 mg/dL), using a statin reduced the LDL-C levels and significantly reduced the risk of myocardial infarction, stroke, and death.

Levels of C-reactive protein increase during inflammation, making its measurement a potentially useful biomarker for improving cardiovascular risk stratification. (Photo credit: Molecule Data Source: PDB ID 1B09)

In addition, findings from other studies presented at the meeting suggested that hsCRP may improve cardiovascular risk stratification beyond such traditional factors as age, blood pressure, total cholesterol, smoking status, and diabetes mellitus.

These results about . . . [Full Text of this Article]

REDUCING CARDIOVASCULAR EVENTS



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?